Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory drugs

Guy Pratt • 4 Apr 2022
BSH 2022
Multiple Myeloma Antibodies CAR-T Iberdomide Teclistamab

Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, talks on promising treatment targets for chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engager (BiTE) immunotherapy in multiple myeloma, including BCMA, GPRC5D, and FcRH5. Prof. Pratt also highlights advances in allogeneic CAR-T therapy and mentions iberdomide, a new promising immunomodulatory drug. With so many new agents, it is now necessary to investigate how to best use and sequence these drugs. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Guy Pratt

1:54
Highlights in myeloma from BSH
Guy Pratt • 4 Apr 2022
1:44
Optimal treatment sequencing in multiple myeloma
Guy Pratt • 4 Apr 2022
2:17
Cilta-cel: a paradigm shift in the treatment of multiple myeloma
Guy Pratt • 4 Apr 2022
1:48
The evolving treatment landscape in multiple myeloma & ongoing research
Guy Pratt • 4 Apr 2022

Related Videos

History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
Novel targets & agents in myeloma
Faith Davies et al. • 3 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
Faith Davies et al. • 3 May 2024
The content of VJHemOnc is intended for healthcare professionals